Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers

by

Call 1 (888) 460-6556 to speak with a counselor.

Drug Development and Industrial Pharmacy, Ahead of Print. (Source: Drug Development and Industrial Pharmacy)

Previous post: Acute urinary retention secondary to buprenorphine administration

Next post: Longitudinal missing data strategies for substance use clinical trials using generalized estimating equations: an example with a buprenorphine trial

All About Suboxone | Oxycontin Treatment Directory | About | Disclaimer | Privacy Policy| Built On The Thesis Theme for WordPress

Get Help

Call 877-841-0923 Now!

X